Overview

Sublingual Cannabidiol for Chronic Pain

Status:
Not yet recruiting
Trial end date:
2023-07-31
Target enrollment:
Participant gender:
Summary
This study involves taking a high-cannabidiol (CBD) sublingual product for 6 weeks in order to assess the impact of CBD on chronic pain, conventional medication use, clinical state, quality of life, cognition, and where applicable, brain structure and function via neuroimaging.
Phase:
Phase 2
Details
Lead Sponsor:
Staci Gruber, Ph.D.
Treatments:
Cannabidiol
Epidiolex